Investigating the effect of magnesium supplementation on cardiorenal syndrome

Phase 2

Recruiting

• Conditions: Heart failure.; Heart failure, unspecified; I50.9

• Registration Number: IRCT20230723058900N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Age over 18 years
Outpatients referred to the clinic diagnosed with chronic heart failure (ECO result with EF less than 40%)
Patients with renal failure or evidence of renal damage (decrease in GFR below normal for more than 3 months or albuminuria above 30 mg/dl in 24-hour urine)
GFR more than 30 mL/min
Serum magnesium below 2 mg/dl

Exclusion Criteria

Current treatment with hemodialysis or peritoneal dialysis
Donated kidney recipient or kidney donor
Coronary artery bypass grafting
Previous parathyroidectomy
Hyperparathyroidism
Current treatment with medication or supplements containing magnesium (antacids)
Recent history of treatment with medicine or supplements containing magnesium
Any condition that interferes with the absorption of magnesium from the digestive system (short bowel syndrome / chronic pancreatitis)
Pregnant mothers, mothers during breastfeeding
Allergy to the contents of the medicine
Patient participation in other intervention trials
Hypothyroidism and hyperthyroidism
Patients showing features of other primary kidney diseases
Urinary tract infection
Any fever associated with infection
Active malignancies
Liver cirrhosis and chronic alcoholism
All people who used cigarettes and other tobacco products
ESRD and stage five CKD
Laxatives and other nephrotoxic drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Score of patients in the Kansas City Cardiomyopathy Questionnaire (KCCQ12). Timepoint: Completing the questionnaire at the beginning of the trial and 3 months after taking the magnesium oxide supplement. Method of measurement: Kansas City Cardiomyopathy Questionnaire.;Measuring patients' performance in the 6-minute walking test. Timepoint: Measuring patients' performance at the beginning of the trial and 3 months after magnesium oxide supplementation. Method of measurement: 6-minute walking test.